Literature DB >> 9727788

The haemodynamic response to exercise in chronic obstructive pulmonary disease: assessment by impedance cardiography.

H J Bogaard1, B M Dekker, B W Arntzen, H H Woltjer, A R van Keimpema, P E Postmus, P M de Vries.   

Abstract

This study aimed to determine the differences in haemodynamic responses to a standard incremental exercise test between outpatients with chronic obstructive pulmonary disease (COPD) and age-matched controls and to discover the relationship between severity of airflow obstruction and exercise haemodynamics in COPD. Twenty-two male patients with COPD (forced expiratory volume in one second (FEV1)/vital capacity (VC))<80% predicted) and 20 age-matched male controls performed an incremental exercise test (10 W x min(-1)) with ventilatory function and changes in stroke volume (deltaSV) and cardiac output (deltaCO) measured by means of electrical impedance cardiography (EIC). Submaximal deltaSV and deltaCO were lower in COPD patients. Peak exercise deltaSV were equal in patients and controls (128+/-33 versus 129+/-29%, p=0.98), whereas peak deltaCO was lower in patients (COPD versus controls: 232+/-71 versus 289+/-54%, p<0.005). In COPD patients, FEV1 (% pred) was significantly correlated to deltaSV at all submaximal exercise intensities, to peak exercise deltaSV and to peak exercise deltaCO. FEV1/VC (% pred) was significantly correlated to deltaSV at 30 and 60 W. In conclusion, in chronic obstructive pulmonary disease an aberrant haemodynamic response to exercise was found, especially in patients with severe airflow obstruction. This aberrant response is related to the degree of airflow obstruction and may limit exercise performance in patients with severe chronic obstructive pulmonary disease.

Entities:  

Mesh:

Year:  1998        PMID: 9727788     DOI: 10.1183/09031936.98.12020374

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Impaired central hemodynamics in chronic obstructive pulmonary disease during submaximal exercise.

Authors:  Joshua R Smith; Bruce D Johnson; Thomas P Olson
Journal:  J Appl Physiol (1985)       Date:  2019-07-11

2.  Influence of expiratory flow-limitation during exercise on systemic oxygen delivery in humans.

Authors:  A Aliverti; R L Dellacà; P Lotti; S Bertini; R Duranti; G Scano; J Heyman; A Lo Mauro; A Pedotti; P T Macklem
Journal:  Eur J Appl Physiol       Date:  2005-08-05       Impact factor: 3.078

3.  Influence of respiratory pressure support on hemodynamics and exercise tolerance in patients with COPD.

Authors:  Cristino Carneiro Oliveira; Cláudia Regina Carrascosa; Audrey Borghi-Silva; Danilo C Berton; Fernando Queiroga; Eloara M V Ferreira; Luiz E Nery; J Alberto Neder; J Alberto Neder
Journal:  Eur J Appl Physiol       Date:  2010-03-06       Impact factor: 3.078

4.  Right atrial pressure affects the interaction between lung mechanics and right ventricular function in spontaneously breathing COPD patients.

Authors:  Bart Boerrigter; Pia Trip; Harm Jan Bogaard; Herman Groepenhoff; Frank Oosterveer; Nico Westerhof; Anton Vonk Noordegraaf
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

5.  Noninvasive measurements of hemodynamic, autonomic and endothelial function as predictors of mortality in sepsis: A prospective cohort study.

Authors:  Jose Carlos Bonjorno Junior; Flávia Rossi Caruso; Renata Gonçalves Mendes; Tamara Rodrigues da Silva; Thaís Marina Pires de Campos Biazon; Francini Rangel; Shane A Phillips; Ross Arena; Audrey Borghi-Silva
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

6.  Lower limb vasodilatory capacity is not reduced in patients with moderate COPD.

Authors:  Surendran Sabapathy; Marc F Awater; Donald A Schneider; Rebecca A Kingsley; Maria T E Hopman; Norman R Morris
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

7.  Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial.

Authors:  Lucas Boeck; Michael Tamm; Peter Grendelmeier; Daiana Stolz
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.